1434 - Anti-Müllerian hormone testing

Page last updated: 10 October 2016

Application Detail

Status

Open

Description of Medical Service

Anti-Müllerian hormone test in female patients for the assessment of ovarian function, including ovarian reserve and ovarian responsiveness before or after gonadotoxic treatment

Indication for test
  1. Patients who are having assessments for fertility preservation prior to gonadotoxic treatment
  2. Long-term follow-up of ovarian function following the completion of gonadotoxic treatment for the intention of determining the complication of gonadotoxic treatment and assess the need for fertility preservation following gonadotoxic treatment or to recommend the start of assisted reproductive treatment.

Description of Medical Condition

  1. Patients diagnosed with malignancy:

    Currently, 5,660 female Australians aged between 0-45 years are diagnosed with cancer each year.

  2. Patients diagnosed with non-malignant conditions receiving gonadotoxic treatment:

Gonadotoxic treatment can be detrimental to the reproductive potential for several non-malignant medical conditions. Examples of these conditions include:
  • gastrointestinal diseases
  • rheumatologic
  • inflammatory bowel diseases (IBDs),
  • rheumatologic disorders
  • non-malignant hematologic conditions
  • autoimmune/vasculitis/glomerular disorders
  • gynaecologic conditions
  • metabolic diseases

Reason for Application

New MBS item

Medical Service Type

Investigative

Previous Application Number

Not Applicable

Associated Documentation

Application Form

-

PICO Confirmation

Consultation Protocol (PDF 1637 KB)
Consultation Protocol (Word 1100 KB)

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

14 April 2016
11 - 12 August 2016

ESC

-

MSAC

-